CD4 and neoplasm: We therefore investigated the ability of TRP-1 CD4+ T cells to control MHC-II-deficient tumour cells by disrupting the Ciita gene encoding the MHC-II transactivator in HCmel12 mouse melanoma cells using CRISPR–Cas9 gene editing (Extended Data Fig. 2j).